These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

346 related items for PubMed ID: 22465268

  • 21. A randomised, double-blinded, placebo-controlled, trial to determine the individual response in bone turnover markers to lasofoxifene therapy.
    Rogers A, Glover SJ, Eastell R.
    Bone; 2009 Dec; 45(6):1044-52. PubMed ID: 19665601
    [Abstract] [Full Text] [Related]

  • 22. Bone Mineral Density and Bone Turnover 10 Years After a Single 5 mg Dose or Two 5-Yearly Lower Doses of Zoledronate in Osteopenic Older Women: An Open-Label Extension of a Randomized Controlled Trial.
    Grey A, Bolland MJ, Horne A, Mihov B, Gamble G, Reid IR.
    J Bone Miner Res; 2022 Jan; 37(1):3-11. PubMed ID: 34585780
    [Abstract] [Full Text] [Related]

  • 23. Effects of Intravenous Zoledronate on Bone Turnover and Bone Density Persist for at Least 11 Years in HIV-Infected Men.
    Bolland MJ, Horne AM, Briggs SE, Thomas MG, Reid I, Gamble GD, Grey A.
    J Bone Miner Res; 2019 Jul; 34(7):1248-1253. PubMed ID: 30870576
    [Abstract] [Full Text] [Related]

  • 24. The relationship of biochemical markers of bone turnover to bone density changes in postmenopausal women: results from the Postmenopausal Estrogen/Progestin Interventions (PEPI) trial.
    Marcus R, Holloway L, Wells B, Greendale G, James MK, Wasilauskas C, Kelaghan J.
    J Bone Miner Res; 1999 Sep; 14(9):1583-95. PubMed ID: 10469288
    [Abstract] [Full Text] [Related]

  • 25. Effect of zoledronic acid compared with raloxifene on bone turnover markers in postmenopausal women with low bone density.
    Bachmann G, Kriegman A, Gonçalves J, Kianifard F, Warren M, Simon JA.
    Menopause; 2011 Aug; 18(8):851-6. PubMed ID: 21796066
    [Abstract] [Full Text] [Related]

  • 26. Prevention of bone loss by clodronate in early postmenopausal women with vertebral osteopenia: a dose-finding study.
    Välimäki MJ, Laitinen K, Patronen A, Puolijoki H, Seppänen J, Pylkkänen L, Aranko SM, Sairanen S, Blåfield H, Rekiaro M, Väisänen K, Kormano M, Mäkinen L, Salmi J, Ala-Kaila K, Perttilä J, Vesterinen K, Koivunoro K, Probone Study Group.
    Osteoporos Int; 2002 Dec; 13(12):937-47. PubMed ID: 12459936
    [Abstract] [Full Text] [Related]

  • 27. Prevention of osteoporosis and uterine effects in postmenopausal women taking raloxifene for 5 years.
    Jolly EE, Bjarnason NH, Neven P, Plouffe L, Johnston CC, Watts SD, Arnaud CD, Mason TM, Crans G, Akers R, Draper MW.
    Menopause; 2003 Dec; 10(4):337-44. PubMed ID: 12851517
    [Abstract] [Full Text] [Related]

  • 28. The effect of continuous oestradiol with intermittent norgestimate on bone mineral density and bone turnover in post-menopausal women.
    Arrenbrecht S, Caubel P, Garnero P, Felsenberg D.
    Maturitas; 2004 Jul 15; 48(3):197-207. PubMed ID: 15207885
    [Abstract] [Full Text] [Related]

  • 29. Early changes in biochemical markers of bone turnover predict the long-term response to alendronate therapy in representative elderly women: a randomized clinical trial.
    Greenspan SL, Parker RA, Ferguson L, Rosen HN, Maitland-Ramsey L, Karpf DB.
    J Bone Miner Res; 1998 Sep 15; 13(9):1431-8. PubMed ID: 9738515
    [Abstract] [Full Text] [Related]

  • 30. Randomized trial of effect of alendronate continuation versus discontinuation in women with low BMD: results from the Fracture Intervention Trial long-term extension.
    Ensrud KE, Barrett-Connor EL, Schwartz A, Santora AC, Bauer DC, Suryawanshi S, Feldstein A, Haskell WL, Hochberg MC, Torner JC, Lombardi A, Black DM, Fracture Intervention Trial Long-Term Extension Research Group.
    J Bone Miner Res; 2004 Aug 15; 19(8):1259-69. PubMed ID: 15231012
    [Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35. Comparison of two different strategies of treatment with zoledronate in HIV-infected patients with low bone mineral density: single dose versus two doses in 2 years.
    Negredo E, Bonjoch A, Pérez-Álvarez N, Ornelas A, Puig J, Herrero C, Estany C, del Río L, di Gregorio S, Echeverría P, Clotet B.
    HIV Med; 2015 Aug 15; 16(7):441-8. PubMed ID: 25944411
    [Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38. Association of bone metabolism related genes polymorphisms with the effect of raloxifene hydrochloride on bone mineral density and bone turnover markers in postmenopausal women with osteoporosis.
    Zhang ZL, He JW, Qin YJ, Huang QR, Liu YJ, Hu YQ, Li M.
    Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2006 Apr 15; 23(2):129-33. PubMed ID: 16604479
    [Abstract] [Full Text] [Related]

  • 39. Intravenous zoledronate improves bone density in adults with cystic fibrosis (CF).
    Chapman I, Greville H, Ebeling PR, King SJ, Kotsimbos T, Nugent P, Player R, Topliss DJ, Warner J, Wilson JW.
    Clin Endocrinol (Oxf); 2009 Jun 15; 70(6):838-46. PubMed ID: 18823395
    [Abstract] [Full Text] [Related]

  • 40. A single infusion of zoledronate prevents bone loss after stroke.
    Poole KE, Loveridge N, Rose CM, Warburton EA, Reeve J.
    Stroke; 2007 May 15; 38(5):1519-25. PubMed ID: 17395868
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 18.